Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva Pharmaeutical Stock Gets Upgrade From Analyst | Barron's
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Pharmaceutical Stock Could Double | Barron's
Teva Pharmaceutical Stock Could Double | Barron's
TEVA | Teva Pharmaceutical Industries Ltd. ADR Stock Overview (U.S.: NYSE) | Barron's
Teva shares drop 3% after rival generic product approved and launched - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Investors wary of Teva-Mylan merger - MarketWatch
Mylan sees opportunity in rival Teva's weakness - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Prosecutors Sue Teva's U.S. Business Over Charitable Donations - WSJ
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva earnings preview: Opioid suits are 'key' - MarketWatch
Teva - Updates, News, Events, Signals & Triggers
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
